Results 41 to 50 of about 136,889 (307)

Zero prevalence of primary drug resistance-associated mutations to protease inhibitors in HIV-1 drug-naive patients in and around Aligarh, India

Journal of Infection in Developing Countries, 2014
Introduction: This study aimed to evaluate the prevalence of resistance mutations in the protease gene of HIV-1 strains isolated from north Indian antiretroviral (ARV) treatment-naive patients and to assess the phylogenetic relatedness of these strains ...
Mohd Azam, Abida Malik, Meher Rizvi, Arvind Rai   +3 more
doaj   +1 more source

HIV-2 Protease resistance defined in yeast cells

Retrovirology, 2006
Background Inhibitors of the HIV-1 Protease currently used in therapeutic protocols, have been found to inhibit, although at higher concentrations, the HIV-2 encoded enzyme homologue.
Raoult Didier, Audoly Gilles, M'Barek Najoua, Gluschankof Pablo   +3 more
doaj   +1 more source

CARD8 inflammasome activation during HIV-1 cell-to-cell transmission

eLife
Our previous work demonstrated that CARD8 detects HIV-1 infection by sensing the enzymatic activity of the HIV protease, resulting in CARD8-dependent inflammasome activation (Kulsuptrakul et al., 2023).
Jessie Kulsuptrakul, Michael Emerman, Patrick S Mitchell   +2 more
doaj   +1 more source

Inhibition Profiling of Retroviral Protease Inhibitors Using an HIV-2 Modular System

Viruses, 2015
Retroviral protease inhibitors (PIs) are fundamental pillars in the treatment of HIV infection and acquired immunodeficiency syndrome (AIDS). Currently used PIs are designed against HIV-1, and their effect on HIV-2 is understudied.
Mohamed Mahdi, Zsófia Szojka, János András Mótyán, József Tőzsér   +3 more
doaj   +1 more source

Cleavage of TANK-Binding Kinase 1 by HIV-1 Protease Triggers Viral Innate Immune Evasion

Frontiers in Microbiology, 2021
Type-I interferons (IFN-I) are the innate immune system’s principal defense against viral infections. Human immunodeficiency virus-1 (HIV-1) has evolved several ways to suppress or evade the host’s innate immunity in order to survive and replicate to ...
Sundararaj Stanleyraj Jeremiah, Kei Miyakawa, Satoko Matsunaga, Mayuko Nishi, Ayumi Kudoh, Akinori Takaoka, Tatsuya Sawasaki, Akihide Ryo   +7 more
doaj   +1 more source

Full length HIV-1 Gag determines protease inhibitor susceptibility within in vitro assays [PDF]

, 2010
OBJECTIVE: There is evidence that gag contributes to protease inhibitor susceptibility in treatment-experienced patients. Moreover, protease inhibitor resistance-associated mutations can arise in gag in the absence of protease mutations in vitro.
Gupta, R.K., Pillay, D., Towers, G.J., Kohli, A., Parry, C.M., McCormick, A.L.   +5 more
core   +1 more source

A novel central nervous system-penetrating protease inhibitor overcomes human immunodeficiency virus 1 resistance with unprecedented aM to pM potency

eLife, 2017
Antiretroviral therapy for HIV-1 infection/AIDS has significantly extended the life expectancy of HIV-1-infected individuals and reduced HIV-1 transmission at very high rates.
Manabu Aoki, Hironori Hayashi, Kalapala Venkateswara Rao, Debananda Das, Nobuyo Higashi-Kuwata, Haydar Bulut, Hiromi Aoki-Ogata, Yuki Takamatsu, Ravikiran S Yedidi, David A Davis, Shin-ichiro Hattori, Noriko Nishida, Kazuya Hasegawa, Nobutoki Takamune, Prasanth R Nyalapatla, Heather L Osswald, Hirofumi Jono, Hideyuki Saito, Robert Yarchoan, Shogo Misumi, Arun K Ghosh, Hiroaki Mitsuya   +21 more
doaj   +1 more source

A modular system to evaluate the efficacy of protease inhibitors against HIV-2.

PLoS ONE, 2014
The human immunodeficiency virus (HIV) protease is a homodimeric aspartyl protease that is crucial for the viral life-cycle, cleaving proviral polyproteins, hence creating mature protein components that are required for the formation of an infectious ...
Mohamed Mahdi, Krisztina Matúz, Ferenc Tóth, József Tőzsér   +3 more
doaj   +1 more source

Pharmacokinetic Parameters of HIV‐1 Protease Inhibitors [PDF]

ChemMedChem, 2020
AbstractSince the beginning of the HIV epidemic, research has been carried out to control the virus. Understanding the mechanisms of replication has given access to the various classes of drugs that over time have transformed AIDS into a manageable chronic disease. The class of protease inhibitors (PIs) gained notice in anti‐retroviral therapy, once it
André L. C. S. Nascimento, Richard P. Fernandes, Christian Quijia, Victor H. S. Araujo, Juliana Pereira, Jerusa S. Garcia, Marcello G. Trevisan, Marlus Chorilli   +7 more
openaire   +2 more sources

ESTUDO COMPARATIVO DE DOCKING MOLECULAR ENTRE O INIBIDOR DE PROTEASE SAQUINAVIR E O CAROTENOIDE BIXINA COMO POTENCIAL INIBIDOR DO VÍRUS HIV TIPO I (1HXB)

Revista Expressão Católica Saúde, 2018
Atualmente, dentre os inibidores de protease de HIV aprovados pela FDA, disponíveis comercialmente, destaca-se o Saquinavir, um fármaco indicado para o tratamento do HIV-1 com imunodeficiência avançada, juntamente com análogos de nucleosídeo ...
Jacilene Silva, Marcia Machado Marinho, José Elieudo da Silva, Emanuelle Machado Marinho, Emmanuel Silva Marinho   +4 more
doaj   +1 more source